Estradiol/progestogen transdermal - Watson

Drug Profile

Estradiol/progestogen transdermal - Watson

Alternative Names: Alnea; Estradiol/progestin transdermal - Watson; Progestin/estradiol transdermal - Watson; Progestogen/estradiol transdermal - Watson; TheraDerm MTX

Latest Information Update: 05 Dec 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Watson Pharmaceuticals
  • Class Estradiol congeners; Estrenes
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Menopausal syndrome; Postmenopausal osteoporosis

Most Recent Events

  • 16 Jan 2001 TheraTech is now called Watson Laboratories
  • 23 Nov 2000 The FDA has issued a Non-Approval Letter for his product.
  • 08 Feb 2000 Preregistration for Menopausal syndrome in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top